“Why Is REPL Stock Soaring 127%…” [July 30, 2026]
August 25, 2026
“The Massachusetts-based biotechnology company announced the favorable outcome following a meeting of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee. The panel voted 10-3 that the results from a key clinical study of the company’s therapy, known as RP1, were both reliable and clinically meaningful for patients with advanced melanoma who had already progressed on prior anti-PD-1 therapy.
Shares of the company soared 127% after hours following the meeting…”
https://finance.yahoo.com/healthcare/articles/why-repl-stock-soaring-127-001439966.html